Tryptophan metabolism and brain function: Focus on kynurenine and other indole metabolites

European Journal of Pharmacology

Volumn 375, Issue 1-3, 1999, Pages 87-100

  Moroni, Flavio ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Encephalopathy hepatic; Ischaemia brain; Kynurenic acid; Kynurenine; NMDA receptor; Oxindole; Quinolinic acid; Tryptophan

Indexed keywords

ENZYME INHIBITOR; INDOLE DERIVATIVE; KYNURENIC ACID; KYNURENINE; KYNURENINE 3 MONOOXYGENASE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR STIMULATING AGENT; QUINOLINIC ACID; TRYPTOPHAN;

ANTICONVULSANT ACTIVITY; APOPTOSIS; BRAIN FUNCTION; BRAIN ISCHEMIA; HEPATIC ENCEPHALOPATHY; HUMAN; METABOLITE; NEUROPHARMACOLOGY; NONHUMAN; PRIORITY JOURNAL; REVIEW; SEDATION; TRYPTOPHAN METABOLISM;

ANIMALS; BRAIN; BRAIN ISCHEMIA; ENZYME INHIBITORS; HYDROLASES; INDOLES; KYNURENINE; RECEPTORS, N-METHYL-D-ASPARTATE; TRYPTOPHAN;

EID: 0033056044     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(99)00196-X     Document Type: Review

References (179)

1. Alberati-Giani D., Malherbe P., Koehler R.C., Lang G., Kiefer V., Lahm H.W., Cesura A.M. Cloning and characterization of a soluble kynurenine aminotransferase from rat brain: identity with kidney cysteine conjugate beta-lyase. J. Neurochem. 64:1995;1448-1455.
2. Alberati-Giani D., Buchli R., Malherbe P., Broger C., Lang G., Koehler R.C., Lahm H.W., Cesura A.M. Isolation and expression of a cDNA clone encoding human kynureninase. Eur. J. Biochem. 239:1996;460-468.
3. Alberati-Giani, D., Ricciardi-Castagnoli, P., Koehler, R.C., Cesura, A.M., 1996b. Regulation of the kynurenine pathway by interferon-gamma in murine cloned macrophages and microglial cells. In: Allegri Filippini, G., Costa, C.V.L., Bertazzo, A. (Eds.), Recent Advances in Tryptophan Research. Plenum, New York, pp. 171-175.
4. Alberati-Giani D., Cesura A.M., Broger C., Warren W.D., Roever S., Malherbe P. Cloning and functional expression of human kynurenine 3-monooxygenase. FEBS Lett. 410:1997;407-412.
5. Allegri Filippini, G., Costa, C.V.L., Bertazzo, A., 1997. Recent Advances in Tryptophan Research: Tryptophan and Serotonin Pathways. Plenum, New York.
6. Baran H., Schwarcz R. Presence of 3-hydroxyanthranilic acid in rat tissues and evidence for its production from anthranilic acid in the brain. J. Neurochem. 55:1999;738-744.
7. Beagles K.E., Morrison P.F., Heyes M.P. Quinolinic acid: in vivo synthesis rates, extracellular concentrations, and intercompartmental distributions in normal and immune-activated brain as determined by multiple-isotope microdialysis. J. Neurochem. 70:1998;281-291.
8. Beal M.F., Kowall N.W., Ellison D.W., Mazurek M.F., Swartz K.J. Replication of the neurochemical characteristics of Huntington's disease by quinolinic acid. Nature. 321:1986;168-171.
9. Beal M.F., Kowall N.W., Swartz K.J., Ferrante R.J., Martin J.B. Differential sparing of somatostatin-neuropeptide Y and cholinergic neurones following striatal excitotoxin lesions. Synapse. 3:1989;38-47.
10. Bender, D.A., 1989. The kynurenine pathway of tryptophan metabolism. In: Stone, T.W. (Ed.), Quinolinic Acid and the Kynurenines. CRC Press, Boca Raton, FL, pp. 3-24.
11. Bender D.A., McCreanor G.M. The preferred route of kynurenine metabolism in the rat. Biochim. Biophys. Acta. 717:1982;56-60.
12. Bengtsson, F., Bergqvist, P.B.F., 1996. Neuropsychiatric implications of brain tryptophan: perturbations appearing in hepatic encephalopathy. In: Allegri Filippini, G., Costa, C.V.L., Bertazzo A. (Eds.), Recent Advances in Tryptophan Research. Plenum, New York, pp. 387-395.
13. Bengtsson F., Bugge M., Johansen K.H., Butterworth R.F. Brain tryptophan hydroxylation in the portocaval shunted rat: a hypothesis for the regulation of serotonin turnover in vivo. J. Neurochem. 56:1991;1069-1074.
14. Blight A.R., Cohen T.I., Saito K., Heyes M.P. Quinolinic acid accumulation and functional deficits following experimental spinal cord injury. Brain. 118:1995;735-752.
15. Bonney E.A., Matzinger P. Much IDO about pregnancy. Nature Medicine. 4:1998;1178-1179.
16. 3H ]Homoquinolinic acid binds to a subpopulation of NMDA receptors and to a novel binding site J. Neurochem. 71:1998;1464-1470.
17. Buchli R., Alberati-Giani D., Malherbe P., Koehler R.C., Broger C., Cesura A.M. Cloning and functional expression of a soluble form of kynurenine/alpha-aminoadipate aminotransferase from rat kidney. J. Biol. Chem. 270:1995;29330-29335.
18. Burke F., Knowles R.G., East N., Balkwill F.R. The role of indoleamine 2,3-dioxygenase in the anti-tumour activity of human interferon-gamma in vivo. Int. J. Cancer. 60:1995;115-122.
19. Cady S.G., Sono M. 1-Methyl-DL-tryptophan,-(3-benzofuranyl)DL-alanine (the oxygen analog of tryptophan) and -[3-benzo(b)thionyl]-DL-alanine (the sulfur analog of tryptophan) are competitive inhibitors for indoleamine 2,3-dioxygenase. Arch. Biochem. Biophys. 291:1991;326-332.
20. Carlin J.M., Ozaki Y., Byrne G.I., Brown R.R., Borden E.C. Interferons and indoleamine 2,3-dioxygenase: role in antimicrobial and antitumor effects. Experientia. 45:1989;535-541.
21. Carpenedo R., Chiarugi A., Russi P., Lombardi G., Carlà V., Pellicciari R., Mattol L., Moroni F. Inhibitors of kynurenine hydroxylase and kynureninase increase cerebral formation of kynurenic acid and have sedative and anticonvulsant activities. Neuroscience. 61:1994;237-244.
22. Carpenedo R., Carlà V., Moneti G., Chiarugi A., Moroni F. Identification and measurement of oxindole (2-indolinone) in the mammalian brain and other rat organs. Anal. Biochem. 244:1997;74-79.
23. Carpenedo R., Mannaioni G., Moroni F. Oxindole, a neurodepressant tryptophan metabolite, accumulates in blood or brain of rats with hepatic failure. J. Neurochem. 70:1998;1998-2003.
24. Cesura, A.M., Alberati-Giani, D., Buchli, R., Broger, C., Koehler, R.C., Vilbois, F., Lahm, H.W., Heitz, M.P., Malherbe, P., 1996. Molecular characterisation of kynurenine pathway enzymes. In: Allegri Filippini, G., Costa, C.V.L., Bertazzo, A. (Eds.), Recent Advances in Tryptophan Research. Plenum, New York, pp. 477-485.
25. Chiarugi, A., Moroni, F., 1999a. Effects of mitochondria and o-methoxybenzoylalanine on 3-hydroxyanthranilic acid dioxygenase activity and quinolinic acid synthesis, J. Neurochem., in press.
26. Chiarugi, A., Moroni, F., 1999b. Quinolinic acid formation in immune-activated mice: studies with (m-nitrobenzoyl)-alanine (mNBA) and 3,4-dimethoxy-[-N-4-(-3-nitrophenyl)thiazol-2yl]-benzenesulfonamide (Ro 61-8048), two potent and selective inhibitors of kynurenine hydroxylase. Neuropharmacology, in press.
27. Chiarugi A., Carpenedo R., Molina M.T., Mattoli L., Pellicciari R., Moroni F. Comparison of the neurochemical and behavioral effects resulting from the inhibition of kynurenine hydroxylase and/or kynureninase. J. Neurochem. 65:1995;1176-1183.
28. Chiarugi A., Carpenedo R., Moroni F. Kynurenine disposition in blood and brain of mice: effects of selective inhibitors of kynurenine hydroxylase and of kynureninase. J. Neurochem. 67:1996;692-698.
29. Choi D.W. Glutamate neurotoxicity and diseases of the nervous system. Neuron. 1:1988;623-634.
30. Connick J., Heywood G.C., Sills G.J., Thomson G.G., Brodie M.J., Stone T.W. Nicotinylalanine increases cerebral kynurenic acid content and has anticonvulsant activity. Gen. Pharmacol. 23:1992;235-239.
31. Cooper A.J., Abraham D.G., Gelbard A.S., Lai J.C.K., Petito C.K. High activities of glutamine transaminase K (dichlorovinylcysteine-lyase) and omega-amidase in the choroid plexus of rat brain. J. Neurochem. 61:1993;1731-1737.
32. Cozzi, A., Carpenedo, R., Moroni, F., 1999. Kynurenine hydroxylase inhibitors reduce ischemic brain damage: studies with (m-nitrobenzoyl)-alanine (mNBA) and 3,4-dimethoxy-[-N-4-(nitrophenyl)thiazol-2yl]-benzensulfonamide (Ro 61-8048) in models of focal or global brain ischemia. J. Cereb. Blood Flow Metab., in press.
33. Dai W., Gupta S.L. Molecular cloning, sequencing and expression of human interferon-gamma-inducible indoleamine 2,3-dioxygenase cDNA. Biochem. Biophys. Res. Commun. 169:1990;1-8.
34. Dai W., Gupta S.L. Regulation of indoleamine 2,3-dioxygenase gene expression in human fibroblasts by interferon gamma. J. Biol. Chem. 265:1990;19871-19877.
35. Danesh U., Hashimoto S., Renkawitz R., Schutz G. Transcriptional regulation of the tryptophan oxygenase gene in rat liver by glucocorticoids. J. Biol. Chem. 258:1983;4750-4753.
36. Danesh U., Gloss B., Schmid W., Schutz G., Schule R., Renkawitz R. Glucocorticoid induction of the rat tryptophan oxygenase gene is mediated by two widely separated glucocorticoid-responsive elements. EMBO J. 6:1987;625-630.
37. DeCastro F.T., Price J.M., Brown R.R. Reduced triphosphopyridinenucleotide requirement for the enzymatic formation of 3OH-L-kynurenine from L-kynurenine. J. Am. Chem. Soc. 78:1956;2904-2905.
38. Decker R.H., Kang H.H., Leach F.R., Henderson L.M. Purification and properties of 3-hydroxyanthranilic acid oxidase. J. Biol. Chem. 236:1961;3076-3082.
39. Decker R.H., Brown R.R., Price J.M. Studies on the biological activity of nicotinylalnine, an analogue of kynurenine. J. Biol. Chem. 238:1963;1049-1053.
40. Dennison Z., Ossenkop K.P., Cain D.P. Effects of central administration of kynurenic acid on spontaneous locomotor activity in kindled rat: a multivariate approach of using the automated Digiscan monitoring system. Pharmacol. Biochem. Behav. 43:1992;807-814.
41. Dong-Ruyl L., Kondo H., Furukawa S., Nakano K. Stimulation of NGF production by tryptophan and its metabolites in cultured mouse astroglial cells. Brain Res. 777:1997;228-230.
42. Dong-Ruyl L., Sawada M., Nakano K. Tryptophan and its metabolite, kynurenine, stimulate expression of nerve growth factor in cultured mouse astroglial cells. Neurosci. Lett. 244:1998;17-20.
43. Du F., Schmidt W.J., Okuno E., Kido R., Koehler R.C., Schwarcz R. Localization of kynurenine aminotransferase immunoreactivity in the rat hippocampus. J. Comp. Neurol. 321:1992;477-487.
44. Du F., Williamson J., Bertram E., Lothman E.W., Okuno E., Schwarcz R. Kynurenine pathway enzymes in a rat model of chronic epilepsy: immunohistochemical study of activated glial cells. Neuroscience. 55:1993;975-989.
45. Dua R.K., Taylor E.W., Phillips R.S. S-aryl-L-cysteine S,S-dioxide: design, synthesis and evaluation of a new class of inhibitors of kynureninase. J. Am. Chem. Soc. 115:1993;1264-1270.
46. Eastman C.L., Guilarte T.R. Citotoxicity of 3-hydroxykynurenine in a neuronal hybrid cell line. Brain Res. 495:1989;225-231.
47. 3H ]-kynurenine Anal. Biochem. 205:1992;257-262.
48. Espey M.G., Tang Y., Morse H.C., Moffet J.R., Namboodiri M.A.A. Localization of quinolinic acid in the murine AIDS model of retrovirus-induced immunodeficiency: implications for neurotoxicity and dendritic cell immunopathogenesis. AIDS. 10:1996;151-158.
49. Feng G., Taylor M.W. Interferon-gamma resistant mutants are defective in the induction of indoleamine 2,3-dioxigenase. Proc. Natl. Acad. Sci. USA. 86:1989;7144-7148.
50. Ferrante R.J., Kowall N.W., Beal M.F., Richardson E.P. Jr., Bird E.D., Martin J.B. Selective sparing of a class of striatal neurones in Huntington's disease. Science. 230:1985;561-563.
51. Flanagan E.M., Erickson J.B., Viveros O.H., Chang S.Y., Reinhard J.F.J. Neurotoxin quinolinic acid is selectively elevated in spinal cord of rats with experimental allergic encephalomyelitis. J. Neurochem. 64:1995;1192-1196.
52. Foster A.C., Collines J.F., Schwarcz R. On the excitotoxic properties of quinolinic acid, 2,3-piperidine dicarboxylic acids and structurally related compounds. Neuropharmacology. 22:1983;1331-1342.
53. Foster A.C., White R.J., Schwarcz R. Synthesis of quinolinic acid by 3-hydroxyantranilic acid oxygenase in rat brain tissue in vitro. J. Neurochem. 47:1986;23-30.
54. Fukui S., Schwarcz R., Rapoport S.I., Takada Y., Smith Q.R. Blood-barrier transport of kynurenines: implications for brain synthesis and metabolism. J. Neurochem. 56:1995;2007-2017.
55. Gill R., Foster A.C., Woodruff G.N. Systemic administration of MK-801 protects against ischemia-induced hippocampal neuronal degeneration in the gerbil. J. Neurosci. 7:1987;3344-3349.
56. Gramsbergen J.B.P., Hodgkins P.S., Rassoulpour A., Turski W.A., Guidetti P., Schwarcz R. Brain-specific modulation of kynurenic acid synthesis in the rat. J. Neurochem. 69:1997;290-298.
57. Green A.R., Woods H.F., Knott P.J., Curzon G. Factors influencing effect of hydrocortisone on rat brain tryptophan metabolism. Nature. 255:1975;170.
58. Guidetti P., Okuno E., Schwarcz R. Characterization of rat brain kynurenine aminotransferases I and II. J. Neurosci. Res. 50:1997;457-465.
59. Guilarte T.R., Wagner H.N. Increased concentrations of 3-hydroxykynurenine in vitamin B-6 deficient neonatal rat brain. J. Neurochem. 49:1987;1918-1926.
60. Hayaishi, O., Yoshida, R., Takikawa, O., Yasui, H., 1984. Indoleamine dioxygenase - a possible biological function. In: Schlossberger, H.G., Kochen, W., Linzen B., Steinhart, H. (Eds.), Progress in Tryptophan and Serotonin Research. De Gruiter, W. Berlin, pp. 33-42.
61. Heyes M.P., Markey S.P. Quantification of quinolinic acid in the rat brain, whole blood and plasma by gas-chromatography and negative chemical ionization mass spectrometry: effects of systemic tryptophan administration on brain and blood quinolinic acid concentrations. Anal. Biochem. 174:1988;349-359.
62. Heyes M.P., Nowak T.S.J. Delayed increase in regional brain quinolinic acid follow transient ischemia in the gerbil. J. Cereb. Blood Flow Metab. 10:1990;660-667.
63. Heyes M.P., Morrison P.F. Quantification of local de novo synthesis versus blood contributions to quinolinic acid concentrations in brain and systemic tissues. J. Neurochem. 68:1997;280-288.
64. Heyes M.P., Saito H., Crowley J.S., Davies L.E., Demitrak M.A., Der M., Dilling L., Kruesi M.J.P., Lackner A., Larsen S.A., Lee K., Leonard H., Markey S.P., Martin A., Milstien S., Mouradian M.M., Pranzatelli M.R., Quearry B.J., Salazar A.M., Smith M.L., Straus S.E., Sunderland T., Swedo S., Tourtelotte W.W. Quinolinic acid and kynurenine pathway metabolism in inflammatory and non-inflammatory neurologic disease. Brain. 115:1992;1249-1273.
65. Heyes M.P., Alchim C.L., Wiley A., Major E.O., Saito K., Markey S.P. Human microglia convert L-tryptophan into the neurotoxin quinolinic acid. Biochem. J. 320:1996;595-597.
66. Heyes M.P., Chen C.Y., Major E.O., Saito K. Different kynurenine pathway enzymes limit quinolinic acid formation by various human cell types. Biochem. J. 326:1997;351-356.
67. Heyes M.P., Saito K., Lackner A., Wiley A., Achim C.L., Markey S.P. Sources of the neurotoxin quinolinic acid in the brain of HIV-1-infected patients and retrovirus-infected macaques. FASEB J. 12:1998;881-896.
68. Hiraku Y., Inoue S., Oikawa S., Yamamoto K., Tada S., Nishino K., Kawanishi S. Metal-mediated oxidative damage to cellular and isolated DNA by certain tryptophan metabolites. Carcinogenesis. 16:1995;349-356.
69. Hirata H., Hayaishi O. Studies on Indoleamine 2,3-dioxygenase. Superoxide anion as substrate. J. Biol. Chem. 250:1975;5960-5966.
70. Hodgkins P.S., Schwarcz R. Interference with cellular energy metabolism reduces kynurenic acid formation in rat brain slices: reversal by lactate and pyruvate. Eur. J. Neurosci. 10:1998;1986-1994.
71. Kapoor R., Okuno E., Kido R., Kapoor V. Immuno-localization of kynurenine aminotransferase in the rat medulla and spinal cord. NeuroReport. 8:1997;3619-3623.
72. Kawai J., Okuno E., Kido R. Organ distribution of rat kynureninase and changes of its activity during development. Enzyme. 39:1988;181-189.
73. Kawata Y., Tani S., Sato M., Katsube Y., Tokushige M. Preliminary X-ray crystallographic analysis of tryptophanase from Escherichia coli. FEBS Lett. 284:1991;270-272.
74. Kim J.P., Choi D.W. Quinolinic acid neurotoxicity in cortical cell culture. Neuroscience. 23:1987;423-432.
75. Knox W.E., Mehler A.H. The adaptive increase of the tryptophan peroxidase oxidase system of liver. Science. 113:1951;237-238.
76. Koehler R.C., Eriksson L.G., Okuno E., Schwarcz R. Localization of quinolinic acid metabolising enzymes in the rat brain: immunohistochemical studies using antibodies to 3-hydroxyanthranilic acid oxygenase and quinolinic acid phosphoribosyltransferase. Neuroscience. 27:1988;49-76.
77. Konan K.V., Taylor M.W. Importance of the two interferon-stimulated response element (ISRE) sequences in the regulation of the human indoleamine 2,3-dioxygenase gene. J. Biol. Chem. 271:1996;19140-19145.
78. Koontz W.A., Shiman R. Beef kidney 3-hydroxyanthranilic acid oxygenase. J. Biol. Chem. 251:1976;368-377.
79. Kotake Y., Masayama T. Uber den mechanismus der kynurenine-bildung aus tryptophan. Hoppe-Seyler's Z. Physiol. Chem. 243:1937;237-244.
80. Lapin I.P. Depressor effect of kynurenine and its metabolites in rats. Life Sci. 19:1976;1479-1484.
81. Lapin I.P. Experimental studies on kynurenine as neuroactive tryptophan metabolites: past, present and future. Trends Pharmacol. Sci. 1:1980;410-413.
82. Lapin I.P. Kynurenines and seizures. Epilepsia. 22:1981;257-265.
83. Lapin I.P. Convulsant action of intracerebroventricularly administered kynurenine sulphate, quinolinic acid and other derivatives of succinic acid and effects of amino acids: structure-activity relationships. Neuropharmacology. 21:1982;1227-1233.
84. Long C.L., Hill H.N., Weinstock I.M., Henderson L.M. Studies on the enzymatic transformation of 3-hydroxyanthranilic acid to quinolinic acid. J. Biol. Chem. 205:1954;411-413.
85. MacKenzie C.R., Hadding U., Daubener W. Interferon-gamma-induced activation of indoleamine 2,3-dioxigenase in cord blood monocyte-derived macrophages inhibits the growth of group B streptococci. J. Infect. Dis. 178:1998;875-878.
86. Maezono K., Tashiro K., Ichihara A. Deduced primary structure of rat tryptophan-2,3-dioxygenase. Biochem. Biophys. Res. Commun. 170:1990;176-181.
87. Malherbe P., Koehler R.C., Da Prada M., Lang G., Kiefer V., Schwarcz R., Lahm H.W., Cesura A.M. Molecular cloning and functional expression of human 3-hydroxyanthranilic acid dioxygenase. J. Biol. Chem. 269:1994;13792-13797.
88. Malherbe P., Alberati-Giani D., Koehler R.C., Cesura A.M. Identification of a mitochondrial form of kynurenine aminotransferase/glutamine transaminase K from rat brain. FEBS Lett. 367:1995;141-144.
89. Mason M. The kynurenine transaminase of rat kidney. J. Biol. Chem. 211:1954;839-844.
90. McDermott C.E., Casciano D.A., Gaertner F.H. Isolation and characterization of an hydroxykynureninase from homogenates of adult mouse liver. Biochem. Biophys. Res. Commun. 51:1973;813-818.
91. McLennan H. A comparison of the effects of NMDA and quinolinic acid on central neurones of the rat. Neurosci. Lett. 46:1984;157-160.
92. Mehler A.H., Knox W.E. Conversion of tryptophan to kynurenine in liver: II. The enzymatic hydrolysis of formylkynurenine. J. Biol. Chem. 187:1950;431-433.
93. Meldrum B. Possible therapeutic applications of antagonists of excitatory amino acid neurotransmitters. Clin. Sci. 68:1985;113-122.
94. Melillo G., Cox G.W., Biragyn A., Sheffler L.A., Varesio L. Regulation of nitric-oxide synthetase mRNA expression by interferon-gamma and picolinic acid. J. Biol. Chem. 269:1994;8128-8133.
95. Miranda A.F., Boegman R.J., Beninger R.J., Jhamandas K. Protection against quinolinic acid mediated excitotoxicity in nigrostriatal dopaminergic neurones by endogenous kynurenic acid. Neuroscience. 78:1997;967-975.
96. Monaghan D.T., Beaton J.A. Quinolinic acid differentiates between forebrain and cerebellar NMDA receptors. Eur. J. Pharmacol. 194:1991;123-125.
97. Moroni F., Lombardi G., Carlà V., Moneti G. The excitotoxin quinolinic acid is present and unevenly distributed in the rat brain. Brain Res. 295:1984;352-355.
98. Moroni F., Lombardi G., Moneti G., Aldinio C. The excitotoxin quinolinic acid is present in the brain of several animal species and its cortical content increases during the aging process. Neurosci. Lett. 47:1984;51-55.
99. Moroni F., Russi P., Lombardi G., Beni M., Carlà V. Presence of kynurenic acid in the mammalian brain. J. Neurochem. 51:1988;177-181.
100. Moroni F., Russi P., Gallo-Mezo M.A., Moneti G., Pellicciari R. Modulation of quinolinic and kynurenic acid content in the rat brain: effects of endotoxins and nicotinylalanine. J. Neurochem. 57:1991;1630-1635.
101. Moroni F., Galli A., Mannaioni G., Carlà V., Cozzi A., Mori F., Marinozzi M., Pellicciari R. NMDA receptor heterogeneity in mammalian tissues: focus on two agonists, (2S,3R,4S) cyclopropylglutamate and the sulphate ester of 4-hydroxy-(S)-pipecolic acid. Naunyn-Schmiedeberg's Arch. Pharmacol. 351:1995;371-376.
102. Moroni, F., Carpenedo, R., Chiarugi, A., 1996. Kynurenine hydroxylase inhibitors as tools to study the role of kynurenine metabolites in the central nervous system. In: Allegri Filippini, G., Costa, C.V.L., Bertazzo, A. (Eds.), Recent Advances in Tryptophan Research. Plenum, New York, pp. 203-210.
103. Moroni F., Carpenedo R., Venturini M., Baraldi M., Zeneroli M.L. Oxindole in pathogenesis of hepatic encephalopathy. Lancet. 351:1998;9119.
104. Moroni F., Cozzi A., Lombardi G., Sourtcheva S., Leonardi P., Carfì M., Pellicciari R. Presynaptic mGlu1 type receptors potentiate transmitter output in the rat cortex. Eur. J. Pharmacol. 347:1998;189-219.
105. Moroni, F., Cozzi, A., Peruginelli, F., Carpenedo, R., Pellegrini-Giampietro, D.E., 1999. Neuroprotective effects of kynurenine-3-hydroxylase inhibitors in models of brain ischemia. In: Steinhart et al., H. (Eds.), ISTRY Meeting 1998. Plenum, in press.
106. Mosca M., Cozzi L., Breton J., Speciale C., Okuno E., Schwarcz R., Benatti L. Molecular cloning of rat kynurenine aminotransferase: identity with glutamine transaminase K. FEBS Lett. 353:1994;21-24.
107. Munn D.H., Zhou M., Attwood J.T., Bondarev I., Conway S.J., Marshall B., Brown C., Mellor A.L. Prevention of allogenic fetal rejection by tryptophan catabolism. Science. 281:1998;1191-1194.
108. Musso T., Gusella G.L., Brooks A., Varesio L. Interleukin-4 inhibits indoleamine 2,3-dioxygenase expression in human monocytes. Blood. 83:1994;1408-1411.
109. Nakagami Y., Saito H., Katsuki H. 3-Hydroxykynurenine toxicity on the rat striatum in vivo. Jpn. J. Pharmacol. 71:1996;183-186.
110. Natalini B., Mattoli L., Pellicciari R., Carpenedo R., Chiarugi A., Moroni F. Synthesis and activity of enantiopure (S) (m-nitrobenzoyl) alanine, a potent kynurenine-3-hydroxylase inhibitor. Bioorg. Med. Chem. Lett. 5:1995;3717-3719.
111. Nozaki K., Beal M.F. Neuroprotective effects of L-kynurenine on hypoxia-ischemia and NMDA lesions in neonatal rats. J. Cereb. Blood Flow Metab. 12:1992;400-407.
112. Okamoto H., Hayaishi O. Intramitochondrial localization of kynurenine aminotransferase. J. Biol. Chem. 245:1970;3603-3608.
113. Okuda S., Nishiyama N., Saito H., Katsuki H. 3-Hydroxykynurenine, an endogenous oxidative stress generator, causes neuronal cell death with apoptotic features and region selectivity. J. Neurochem. 70:1998;299-307.
114. Okuno, E., Kido, R., 1991. Kynureninase and kynurenine,3-hydroxylase in mammalian tissue. In: Schwarcz et al., R. (Eds.), Kynurenine and Serotonin Pathways. Plenum, New York, pp. 167-175.
115. Okuno E., Nakamura M., Schwarcz R. Two kynurenine aminotransferases in human brain. Brain Res. 542:1991;307-312.
116. Olney J.W. Excitotoxic amino acids and neuropsychiatric disorders. Annu. Rev. Pharmacol. Toxicol. 30:1990;47-71.
117. Olney J.W., Labruyere J., Price M. Pathological changes induced in cerebrocortical neurones in phencyclidine related drugs. Science. 244:1989;1360-1362.
118. Orcutt J.A., Prytherch J.P., Konicov M., Michaelson S.M. Some new compounds exhibiting selective CNS-depressant activities: Part 1. Preliminary observations. Arch. Int. Pharmacodyn. 152:1964;121-131.
119. Parli C.J., Krieter P., Schmidt B. Metabolism of 6-chlorotryptophan to 4-chloro-3-hydroxyanthranilic acid: a potent inhibitor of 3-hydroxyanthranilic acid oxidase. Arch. Biochem. Biophys. 203:1980;161-166.
120. Pellegrini-Giampietro D.E., Cherici G., Alesiani M., Carlà V., Moroni F. Excitatory amino acid release and free radical formation may cooperate in the genesis of ischemia-induced neuronal damage. J. Neurosci. 10:1990;1035-1041.
121. Pellegrini-Giampietro D.E., Cozzi A., Moroni F. The glycine antagonist and free radical scavenger 7-Cl-thio-kynurenate reduces CA1 ischemic damage in the gerbil. Neuroscience. 63:1994;701-709.
122. Pellicciari R., Natalini B., Costantino G., Mahmoud M.R., Mattoli L., Sadeghpour B.M., Moroni F., Chiarugi A., Carpenedo R. Modulation of the kynurenine pathway in search for new neuroprotective agents. Synthesis and preliminary evaluation of (m-nitrobenzoyl)alanine, a potent inhibitor of kynurenine-3-hydroxylase. J. Med. Chem. 37:1994;647-655.
123. Perkins M.N., Stone T.W. An iontophoretic investigation of the actions of convulsant kynurenines and their interactions with the endogenous excitant quinolinic acid. Brain Res. 247:1982;184-187.
124. Perkins M.N., Stone T.W. Specificity of kynurenic acid as an antagonist of synaptic transmission in rat hippocampal slices. Neurosci. Lett. 18:1982;432-436.
125. Perkins M.N., Stone T.W. Pharmacological and regional variations of quinolinic acid-evoked excitations in the rat central nervous system. J. Pharmacol. Exp. Ther. 226:1983;551-557.
126. Perry S.J., Schofield M.A., MacFarlane M., Lock E.A., Gibson G.C., Goldfarb P.S. Isolation and expression of a cDNA coding for rat kidney cytosolic cysteine conjugate beta-lyase. Mol. Pharmacol. 43:1993;660-665.
127. Pfefferkorn, E.R., 1984. Interferon-gamma blocks the growth of toxoplasma Gondii in human fibroblasts by inducing the host cells to degrade tryptophan. Proc. Natl. Acad. Sci. USA, pp. 908-912.
128. Pinelli A., Ossi C., Colombo R., Tofanetti O., Spazzi L. Experimental convulsions in rats induced by intraventricular administration of kynurenine and structurally related compounds. Neuropharmacology. 23:1984;333-337.
129. Poeggeler B., Rassoulpour A., Guidetti P., Wu H.Q., Schwarcz R. Potentiation of striatal NMDA excitotoxicity in the rat by D-amphetamine: a role for kynurenic acid? Soc. Neurosci. Abstr. 24:1998;461.
130. Reinhard, J.F.J., Erickson, J.B., Flanagan, E.M., 1994. Quinolinic acid in neurological disease: opportunity for novel drug discovery. In: Advances in Pharmacology. Academic Press, London, pp. 85-118.
131. Reinhard J.F.J., Flanagan E.M., Madge D.J., Iyer R., Salter M. Effects of 540C91 [(E)-3-[2-(4′-pyridyl)-vinyl]-1H-indole], an inhibitor of hepatic tryptophan dioxygenase, on brain quinolinic acid in mice. Biochem. Pharmacol. 51:1996;159-163.
132. Roberts R.C., McCarthy K.E., Du F., Ottersen O.P., Okuno E., Schwarcz R. 3-Hydroxyanthranilic acid oxygenase-containing astrocytic processes surround glutamate-containing axon terminals in the rat striatum. J. Neurosci. 12:1995;1150-1161.
133. Roever S., Cesura A.M., Huguenin P., Kettler R., Szente A. Synthesis and biochemical evaluation of N-(4-phenylthiazol-yl)benzenesulfonamides as high-affinity inhibitors of kynurenine 3-hydroxylase. J. Med. Chem. 40:1997;4378-4385.
134. Rogawski M. The NMDA receptor, NMDA antagonists and epilepsy therapy. Drugs. 44:1992;279-292.
135. Russi P., Alesiani M., Lombardi G., Davolio P., Pellicciari R., Moroni F. Nicotinylalanine increases the formation of kynurenic acid in the brain and antagonizes convulsions. J. Neurochem. 59:1992;2076-2080.
136. Saito K., Chen C.Y., Masana M., Crowley J.S., Markey S.P., Heyes M.P. 4-Chloro-3-hydroxyanthranilate, 6-chlorotryptophan and norharmane attenuate quinolinic acid formation by interferon-gamma-stimulate monocytes (THP-1 cells). Biochem. J. 291:1993;11-14.
137. Saito K., Crowley J.S., Markey S.P., Heyes M.P. A mechanism for increased quinolinic acid formation following acute systemic immune stimulation. J. Biol. Chem. 268:1993;15496-15503.
138. Saito K., Nowak T.S.J., Markey S.P., Heyes M.P. Mechanism of delayed increase in kynurenine pathway metabolism in damaged brain regions following transient cerebral ischemia. J. Neurochem. 60:1993;180-192.
139. Saito K., Markey S.P., Heyes M.P. 6-Chloro-D,L-tryptophan, 4-chloro-3-hydroxyanthranilate and dexamethasone attenuate quinolinic acid accumulation in brain and blood following systemic immune activation. Neurosci. Lett. 178:1994;211-215.
140. Salter M., Hazelwood R., Pogson C.I., Iyer R., Madge D.J. The effects of a novel and selective inhibitor of tryptophan 2,3-dioxygenase on tryptophan and serotonin metabolism in rat. Biochem. Pharmacol. 49:1995;1435-1442.
141. Santamaria A., Altagracia M., Solis F., Kravzov J., Ordaz H., Gonzalez L., Rios C. Kynurenine and probenecid prevent quinolinic acid-induced neurotoxicity in rat corpus striatum. Proc. West. Pharmacol Soc. 37:1994;29-30.
142. Scharfman H.E., Ofer A. Pretreatment with L-kynurenine, the precursor to the excitatory amino acid antagonist kynurenic acid, suppress epileptiform activity in combined entorhinal/hippocampal slices. Neurosci. Lett. 224:1997;115-118.
143. Schmid W., Scherer G., Danesh U., Zentgraf H., Matthias P., Strange C.M., Rowekamp W., Schutz G. Isolation and characterization of the rat tryptophan oxygenase gene. EMBO J. 1:1982;1287-1289.
144. Schutz G., Chow E., Feigelson P. Regulatory properties of hepatic tryptophan oxygenase. J. Biol. Chem. 247:1972;5333-5337.
145. Schwarcz R., Whetsell W.O., Mangano R.M. Quinolinic acid: an endogenous metabolite that produces axon-sparing lesions in rat brain. Science. 219:1983;316-318.
146. Schwarcz R., Okuno E., White R.J., Bird E.D., Whetsell W.O. 3OH-anthranilic acid oxygenase activity is increased in the brains of Huntington disease victims. Proc. Natl. Acad. Sci. USA. 85:1988;4079-4081.
147. Schwarcz, R., Guidetti, P., Poeggeler, B., Wu, H.Q., Rassoulpour, A., 1999. Modulation of neuronal viability by neuroactive kynurenines. In: Steinhart et al., H. (Eds.), ISTRY 1998. Plenum, in press.
148. Sekkai D., Guittet O., Lemaire G., Tenu J.P., Lepoivre M. Inhibition of nitric oxide synthase expression and activity in macrophages by 3-hydroxyanthranilic acid, a tryptophan metabolite. Arch. Biochem. Biophys. 340:1997;117-123.
149. Shemer Y., Kol R., Sarov I. Tryptophan reversal of recombinant human gamma-interferon inhibition of C. Trachomatis growth. Curr. Microbiol. 16:1987;9-13.
150. Simon R.P., Swan J.H., Griffiths T., Meldrum B.S. Blockade of N-methyl-D-aspartate receptors may protect against ischemic damage in the brain. Science. 226:1984;850-852.
151. Sing L., Oles R.J., Tricklebank M.D. Modulation of seizure susceptibility in the mouse by the strychnine-insensitive glycine recognition site of the NMDA receptor/ion channel complex. Br. J. Pharmacol. 99:1990;285-288.
152. Small, D.L., Buchan, A.M., 1997. NMDA antagonists: their role in neuroprotection. In: Green, A.R., Cross, A.J. (Eds.), Neuroprotective Agents and Cerebral Ischaemia. Academic Press, San Diego, pp. 137-148.
153. Speciale C., Hares K., Schwarcz R., Brooks A. High affinity uptake of L-kynurenine by a Na+-independent transporter of neutral amino acids in astrocytes. J. Neurosci. 9:1989;2066-2072.
154. Speciale, C., Wu, H.Q., Cini, M., Marconi, M., Varasi, M., Schwarcz, R., 1996. (R,S)-3,4-dichlorobenzoylalanine (FCE 28833A) causes a large and persistent increase in brain kynurenic acid levels in rats. Eur. J. Pharmacol., pp. 263-267.
155. Stevens J.L. Isolation and characterization of a rat liver enzyme with both cysteine conjugate beta-lyase and kynureninase activity. J. Biol. Chem. 260:1985;7945-7950.
156. Stevens J.L., Ayoubi N., Robbins J.D. The role of mitochondrial matrix enzymes in the metabolism and toxicity of cysteine conjugates. J. Biol. Chem. 263:1988;3395-3399.
157. Stone T.W. Neuropharmacology of quinolinic and kynurenic acids. Pharmacol. Rev. 45:1993;309-379.
158. Stone T.W., Perkins M.N. Quinolinic acid: a potent, endogenous excitant at amino acid receptors in CNS. Eur. J. Pharmacol. 72:1981;411-412.
159. Stone T.W., Connick J. Quinolinic acid and other kynurenines in the central nervous system. Neuroscience. 15:1985;507-617.
160. Swartz K.J., During M.J., Freese A., Beal M.F. Cerebral synthesis and release of kynurenic acid: an endogenous antagonist of excitatory amino acid receptors. J. Neurosci. 10:1990;2965-2973.
161. Takikawa, O., Habara-Ohkubo, A., Yoshida, R., 1991. Induction of indoleamine 2,3-dioxygenase in tumor cells transplanted into allogenic mouse: interferon-gamma is the inducer. In: Schwarcz, R., Young, S.N., Brown, R.R. (Eds.), Kynurenine and Serotonin Pathways. Plenum, New York, pp. 437-444.
162. Taylor M.W., Feng G. Relationship between interferon gamma, indoleamine 2,3-dioxygenase, and tryptophan catabolism. FASEB J. 5:1991;2516-2522.
163. Thomas S.R., Mohr D., Stocker R. Nitric oxide inhibits indoleamine 2,3-dioxygenase activity in interferon gamma primed mononuclear phagocytes. J. Biol. Chem. 269:1994;14457-14464.
164. Toma S., Nakamura M., Tone S., Okuno E., Kido R., Breton J., Avanzi N., Cozzi L., Speciale C., Mostardini M., Gatti S., Benatti L. Cloning and recombinant expression of rat and human kynureninase. FEBS Lett. 408:1997;5-10.
165. Tone S., Takikawa O., Habara-Ohkubo A., Kadoya A., Yoshida R., Kido R. Primary structure of human indoleamine 2,3-dioxygenase deduced from the nucleotide sequence of its cDNA. Nucleic Acid Research. 18:1990;367.
166. Uemura T., Hirai K. L-kynurenine 3,monooxygenase from mitochondrial outer membrane of pig liver: purification, some properties and monoclonal antibodies directed to the enzyme. J. Biochem. 123:1998;253-262.
167. Varesio L., Clayton E., Blasi R., Ruffman R., Radzioch D. Picolinic acid, a catabolite of tryptophan, as the second signal in the activation of interferon gamma primed macrophages. J. Immunol. 145:1990;4265-4269.
168. Vartanian M.G., Taylor C.P. Different stereoselectivity of the enantiomers of HA-966 (3-amino-1-hydroxy-2-pyrrolidinone) for neuroprotective and anticonvulsant actions in vivo. Neurosci. Lett. 133:1991;109-112.
169. Vécsei L., Miller J., MacGarvey U., Beal M.F. Kynurenine and probenecid inhibit pentylenetetrazol and NMDA-induced seizures and increase kynurenic acid concentrations in the brain. Brain Res. Bull. 28:1991;233-238.
170. Vederas J.C., Schleicher E., Tsai M., Floss H.G. Stereochemistry and mechanism of reactions catalyzed by tryptophanase from Escherichia coli. J. Biol. Chem. 253:1978;5350-5354.
171. Watanabe Y., Yoshida R., Sono M., Hayaishi O. Immunohistochemical localization of indoleamine 2,3-dioxygenase in the argyrophilic cells of rabbit duodenum and thyroid gland. J. Histochem. Cytochem. 29:1981;623-632.
172. Whetsell W.O., Schwarcz R. Prolonged exposure to submicromolar concentrations of quinolinic acid causes excitotoxic damage in organotypic cultures of rat cortico-striatal system. Neurosci. Lett. 97:1989;271-275.
173. Wolf H. Studies on tryptophan metabolism in man. Scand. J. Clin. Lab. Invest. 136S:1974;1-186.
174. Wolfensberger M., Amsler U., Cuenod M., Foster A.C., Whetsell W.O., Schwarcz R. Identification of quinolinic acid in rat and human brain tissue. Neurosci. Lett. 41:1984;247-252.
175. Yoshida R., Hayaishi O. Indoleamine 2,3-dioxygenase. Meth. Enzymol. 142:1987;188-195.
176. Yoshida R., Urade Y., Tokuda M., Hayaishi O. Induction of indoleamino 2,3-dioxygenase in mouse lung during virus infection. Proc. Natl. Acad. Sci. USA. 76:1979;4084-4086.
177. Yoshida R., Oku T., Imanishi J., Kishida T., Hayaishi O. Interferon: a mediator of indoleamine 2,3-dioxygenase induction by lipopolysaccharide, Poly(I)-Poly(C) and pokeweed mitogen in mouse lung. Arch. Biochem. Biophys. 249:1986;596-604.
178. Young S.N. Mechanism of decline in rat brain 5-HT after induction of liver tryptophan pyrrolase by hydrocortisone: roles of tryptophan catabolism and kynurenine synthesis. Br. J. Pharmacol. 74:1981;695-700.
179. Yuan W., Collado-Hidalgo A., Yufit T., Taylor M.W., Varga J. Modulation of cellular tryptophan metabolism in human fibroblasts by transforming growth factor beta: selective inhibition of indoleamine 2,3-dioxygenase and tryptophanyl-tRNA synthetase gene expression. J. Cell. Physiol. 177:1998;174-186.